Show simple item record

dc.contributor.authorLei, Wei
dc.contributor.authorVekariya, Rakesh H.
dc.contributor.authorAnanthan, Subramaniam
dc.contributor.authorStreicher, John M.
dc.date.accessioned2020-09-10T21:54:43Z
dc.date.available2020-09-10T21:54:43Z
dc.date.issued2020-01
dc.identifier.citationLei, W., Vekariya, R. H., Ananthan, S., & Streicher, J. M. (2020). A novel mu-delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models. The Journal of Pain, 21(1-2), 146-160.en_US
dc.identifier.issn1526-5900
dc.identifier.pmid31201990
dc.identifier.doi10.1016/j.jpain.2019.05.017
dc.identifier.urihttp://hdl.handle.net/10150/643323
dc.description.abstractNumerous studies have demonstrated a physiological interaction between the mu opioid receptor (MOR) and delta opioid receptor (DOR) systems. A few studies have shown that dual MOR-DOR agonists could be beneficial, with reduced tolerance and addiction liability, but are nearly untested in chronic pain models, particularly neuropathic pain. In this study, we tested the MOR-DOR agonist SRI-22141 in mice in the clinically relevant models of HIV Neuropathy and Chemotherapy-Induced Peripheral Neuropathy (CIPN). SRI-22141 was more potent than morphine in the tail flick pain test and had equal or enhanced efficacy versus morphine in both neuropathic pain models, with significantly reduced tolerance. SRI-22141 also produced no jumping behavior during naloxone-precipitated withdrawal in CIPN or nayve mice, suggesting that SRI-22141 produces little to no dependence. SRI-22141 also reduced tumor necrosis factor-alpha and cyclooxygenase-2 in CIPN in the spinal cord, suggesting an anti-inflammatory mechanism of action. The DOR-selective antagonist naltrindole strongly reduced CIPN efficacy and anti-inflammatory activity in the spinal cord, without affecting tail flick antinociception, suggesting the importance of DOR activity in these models. Overall, these results provide compelling evidence that MOR-DOR agonists could have strong efficacy with reduced side effects and an anti-inflammatory mechanism in the treatment of neuropathic pain. Perspective: This study demonstrates that a MOR-DOR dual agonist given chronically in chronic neuropathic pain models has enhanced efficacy with strongly reduced tolerance and dependence, with a further anti-inflammatory effect in the spinal cord. This suggests that MOR-DOR dual agonists could be effective treatments for neuropathic pain with reduced side effects. (C) 2020 U.S. Association for the Study of Pain. Published by Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipNational Institutes of Healthen_US
dc.language.isoenen_US
dc.publisherElsevier BVen_US
dc.rightsCopyright © 2020 U.S. Association for the Study of Pain. Published by Elsevier Inc. All rights reserved.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en_US
dc.subjectMu opioid receptoren_US
dc.subjectdelta opioid receptoren_US
dc.subjectHIV neuropathyen_US
dc.subjectchemotherapy-induced neuropathyen_US
dc.subjecttoleranceen_US
dc.subjectdependenceen_US
dc.subjectneuroinflammationen_US
dc.titleA Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Modelsen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Med, Dept Pharmacolen_US
dc.identifier.journalJOURNAL OF PAINen_US
dc.description.note12 month embargo; published 12 June 2019en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal accepted manuscripten_US
dc.identifier.piiS152659001930745X
dc.source.journaltitleThe Journal of Pain
dc.source.volume21
dc.source.issue1-2
dc.source.beginpage146
dc.source.endpage160
refterms.dateFOA2020-06-12T00:00:00Z


Files in this item

Thumbnail
Name:
A_Novel_Mu-Delta_Opioid_Agonist.pdf
Size:
1.134Mb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record